Jyong Biotech Ltd. (MENS): Long-Term Debt

Annual figures by period end, from SEC filings.

$2.12M

As of 2025-12-31

Period ended	Long-Term Debt	Change YoY	Source filing
2025-12-31	$2.12M	n/a	2026-05-15, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Long-Term Debt	Change YoY
Jyong Biotech Ltd. (MENS)	2025-12-31	$2.12M	n/a
Emmaus Life Sciences, Inc. (EMMA)	2025-12-31	$27.13M	-6.3%
Propanc Biopharma, Inc. (PPCB)	2025-06-30	$537.9K	+34.7%
Gain Therapeutics, Inc. (GANX)	2025-12-31	$401.0K	-8.6%
Clene Inc. (CLNN)	2025-12-31	$17.79M	n/a
HCW Biologics Inc. (HCWB)	2025-12-31	$0	-100.0%
Tempest Therapeutics, Inc. (TPST)	2024-12-31	$6.40M	-39.0%
Elicio Therapeutics, Inc. (ELTX)	2025-12-31	$10.00M	n/a
Yarrow Bioscience, Inc. (YARW)	2025-12-31	$0	n/a

Compare MENS, EMMA, PPCB, GANX side by side · Screen every company in Pharmaceutical Preparations ↗